Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9284555 | 0.93 | SAT1 (0.72) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL4388966 | 0.86 | SAT1 (0.45) | SAT1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL2148609 | 0.80 | BLM (0.49) | SAT1CYP2C19MEN1KMT2ACYP1A2 | |
| Water SCHEMBL5319737 | 0.79 | BLM (0.47) | SAT1CYP2C19MEN1KMT2ACYP1A2 | |
| SCHEMBL5246842 | 0.79 | SAT1 (0.53) | SAT1S1PR2S1PR4S1PR1S1PR3 | |
| Water SCHEMBL8576389 | 0.79 | BLM (0.47) | SAT1CYP2C19MEN1KMT2ACYP1A2 | |
| Water SCHEMBL6575430 | 0.79 | BLM (0.47) | SAT1CYP2C19MEN1KMT2ACYP1A2 | |
| Water SCHEMBL9325750 | 0.77 | SAT1 (0.51) | SAT1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL4098549 | 0.77 | SAT1 (0.53) | SAT1CYP2C19MEN1GLAKMT2A | |
| SCHEMBL18501085 | 0.73 | SAT1 (0.70) | SAT1CYP2C19MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090312-A1 | METHODS OF USE RELATED TO XEROSTOMIA | MEDIMMUNE LLC (US) | 2013-04-11 | — | — | US | disclosed |
| US-20110166108-A1 | METHODS OF USE RELATED TO XEROSTOMIA | MEDIMMUNE, LLC. | 2011-07-07 | — | — | US | disclosed |
| US-20090325814-A1 | BIOMOLECULE DETECTION REAGENT AND METHOD FOR DETECTING BIOMOLECULE USING THE SAME | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7629333-B2 | Stable amorphous amifostine compositions and methods for the preparation and use of same | MEDIMMUNE, LLC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080027030-A1 | Pharmaceutical compositions comprising amifostine and related compounds | STOGNIEW MARTIN | 2008-01-31 | — | — | US | disclosed |
| EP-1764103-A2 | Crystalline amifostine compositions and methods for the preparation and use of same | Medimmune Oncology, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7151094-B2 | Topical administration of amifostine and related compounds | MEDLMMUNE ONCOLOGY, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060270636-A1 | Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds | MEDIMMUNE ONCOLOGY, INC. | 2006-11-30 | — | — | US | disclosed |
| US-7105575-B2 | Methods for the treatment of neuro- disorders using aminothiol compounds | MEDIMMUNE ONCOLOGY INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1039887-B1 | USE OF AMINOTHIOL COMPOUNDS FOR THE TREATMENT OF NEURO- AND NEPHRO-DISORDERS AND THERAPEUTIC TOXICITIES | MEDIMMUNE ONCOLOGY INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6407278-B2 | HEAT RESISTANCE DOSAGE FORMS | MEDIMMUNE ONCOLOGY, INC. | 2002-06-18 | — | — | US | disclosed |
| US-6384259-B1 | HEAT RESISTANT, STERILE DOSAGE SUITABLE FOR RECONSTITUTION WITH A VEHICLE INTO AN INJECTIBLE, PARTICLE-FREE PRODUCT FOR PARENTERAL ADMINISTRATION | MEDIMMUNE ONCOLOGY, INC. | 2002-05-07 | — | — | US | disclosed |
| US-20020010357-A1 | STABLE AMORPHOUS AMIFOSTINE COMPOSITIONS AND DOSAGE FORM | CLINIGEN GROUP PLC (GB) | 2002-01-24 | — | — | US | disclosed |
| EP-1131103-A1 | STABLE AMORPHOUS AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME | U.S. BIOSCIENCE, INC. (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6239119-B1 | PROTECTING MUCOSAL TISSUE FROM DAMAGE ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPEUTIC TREATMENT OF CANCERS, AVOID THE SIDE EFFECTS OF SYSTEMICALLY APPLIED RADIO/CHEMO PROTECTANTS. | MEDIMMUNE ONCOLOGY, INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2000029025-A1 | STABLE AMORPHOUS AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME | U.S. BIOSCIENCE, INC. (US) | 2000-05-25 | — | — | WO | disclosed |
| US-5994409-A | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds | U.S. BIOSCIENCE, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5591731-A | Crystalline amifostine compositions | U.S. BIOSCIENCE, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| US-5424471-A | Stabilizing the drug for storage stability, heat resistance by hydrating in an alcohol water solution, vacuum drying to form solid crystals | U.S. BIOSCIENCE, INC. (US) | 1995-06-13 | — | — | US | disclosed |
| WO-1994003179-A1 | CRYSTALLINE AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME | U.S. BIOSCIENCE, INC. (US) | 1994-02-17 | — | — | WO | disclosed |